Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, XERIS BIOPHARMA HOLDINGS, INC. reported revenue of $292M, up 43.7% year over year. Operating margin was 8.5% and net margin 0.2%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from XERS's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $292M | 8.5% | 0.2% |
| FY2024 | $203M | -16.6% | -27.0% |
| FY2023 | $164M | -26.8% | -38.0% |
| FY2022 | $110M | -74.3% | -85.9% |
| FY2021 | $50M | -232.2% | -247.5% |
How does XERS compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.